Analogs of glucagon exhibiting GIP receptor activity

Patent metadata

Field	Value
Publication number	US-9868772-B2
Application number	US-201314408813-A
Country	US
Kind code	B2
Filing date	Jun 18, 2013
Priority date	Jun 21, 2012
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.

First claim

What is claimed:

1. A glucagon analog exhibiting glucagon, GLP-1 and GIP receptor activity, said analog consisting of the sequence of SEQ ID NO: 12.

2. A pharmaceutical composition comprising the glucagon analog of claim 1 and a pharmaceutically acceptable carrier.

3. A glucagon analog exhibiting glucagon, GLP-1 and GIP receptor activity, said analog selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 143 and SEQ ID NO: 146.

Assignees

• Univ Indiana Res & Tech Corp
• Hoffmann La Roche

Inventors

• Dimarchi Richard D
• Smiley David L
• Bleicher Konrad H
• Kitas Eric A

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P7/12

  Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10) · CPC title

• A61P5/48

  of the pancreatic hormones · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title